Loading
Life sciences · Journal article
Discover Oncology · October 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Psammocarcinoma is a rare variant of serous carcinoma of ovarian or primary peritoneal origin, typically characterized by low-grade nuclear atypia, abundant psammoma body formation, and extensive calcification on computed tomography (CT) imaging. Herein, we report two cases of advanced-stage ovarian psammocarcinoma in a 70-year-old woman (FIGO stage ⅣB) and a 58-year-old woman (FIGO stage ⅢC). Both patients underwent diagnostic laparoscopy with biopsy, and primary debulking surgery was not performed. Despite divergent management strategies, ranging from surveillance to platinum-taxane chemotherapy, both patients remained radiologically stable during follow-up. Furthermore, a comprehensive literature review of 93 previously reported cases (37 primary peritoneal and 56 primary ovarian) was conducted. Our review highlights that serum cancer antigen 125 (CA-125) may be a useful biomarker for disease assessment and follow-up, although it is not uniformly elevated at diagnosis. While optimal surgical cytoreduction remains the cornerstone of management, advanced cases require individualized multidisciplinary strategies, potentially including chemotherapy and, in selected receptor-positive patients, endocrine therapy. Prognosis appears more favorable than that of conventional high-grade serous carcinoma, but careful preoperative evaluation and vigilant post-treatment surveillance remain essential.